Part I: Skin Deep – The Role of Endocannabinoid System in Cutaneous Below the epidermis lies the dermis, a layer composed of the fibrillar structural protein of proliferation and migration, sending cells towards the surface of the skin to. Jun 10, In the skin, cannabinoid lipids, whether of endogenous or . As detailed below, however, the ability of cannabinoids to evoke pain under Thus, endocannabinoids and their receptors constitute part of an adaptive system to regulate .. TRPV2 both by promoting its translocation to the cell surface and by . Finally, the therapeutic potential of the endocannabinoid signaling system is discussed .. in different layers of the skin, and in some adnexal structures ( sweat glands, of acute, inflammatory and neuropathic pain models are reviewed below. . onto the plantar surface of the paw through the floor of a glass platform .
System Your The Skin Surface: and Endocannabinoid Beneath the
Interestingly, it appears that it is not just acupuncture that kindles the endocannabinoid system ECS , but cannabis does that as well. CB1 receptors occur mostly in the brain of almost all mammals while CB2 is present in the body tissues, organs and throughout the central nervous system.
Basically, the ECS is known to regulate everything from immune system responses, pain sensations and inflammation to appetite, mood, memory, as well as overall metabolism.
Like marijuana, acupuncture appears to kindle the body in various ways, working to heal, optimize, and heal major systems of the body, including, the endocannabinoid system. The science being acupuncture explains that the analgesic, pain-alleviating effects of inserting needles just beneath the human skin in key points, basically, does something other than making the patient look like a porcupine.
Interestingly, when these are released via the placement of tiny needles, pain and inflammation ease a bit. As acupuncture starts to help the damaged body areas to function better, it also stirs up the endocannabinoid system with an aim of regulating the body and controlling pain.
And so, in the future, it is highly likely that research will study not only at how acupuncture stirs up the ECS but also how medical cannabis itself can help to maintain such stimulations or triggers, even between treatments, to restore damaged systems to optimal health.
Acupuncture boasts of numerous success stories of assisting patients to lose weight, regain health and free themselves from addictions. Likewise, marijuana is popularly used to boost the effectiveness of various types of holistic healing. Using it together with acupuncture might be the ideal combination to improving your health. Our CBD products are not for use by or sale to persons under the age of 18 and should not be used if you are pregnant or nursing. Consult with a physician before use if you have a serious medical condition or use prescription medications.
The information on our website and any other communication regarding legality which you may receive from any representative of Compassionate Certification Centers is for informational purposes only and not for the purpose of providing legal advice. You must make your own judgment regarding whether you should purchase CBD in your jurisdiction.
You should contact your attorney to obtain more specific guidance. In wild-type mice, inactivation of TRPV1 expressing sensory terminals with the vanilloid, resiniferatoxin, similarly augmented Oxa-induced ear edema.
The authors concluded, instead, that the TRPV1 must also trigger the release of one or more anti-inflammatory agents from peptidergic nerve terminals. Why might interference with TRPV1 function suppress Oxa-induced inflammation in one study and augment it in another? Lifelong absence of TRPV1 in the knockout studies might have resulted in compensatory effects in other systems that regulate cutaneous inflammation. The use of immunologically distinct mouse strains and differences in the doses and anatomical sites of Oxa administration between studies may represent two additional confounding variables.
Certain dose-dependent cannabinoid effects in skin have been attributed to both direct and indirect modulation of TRPV1. Anandamide has also been shown to suppress proliferation and promote cell death in human keratinocytes in culture, both through actions on CB1 and by activating TRPV1-mediated calcium influx.
Together, the findings described above support a model in which cannabinoids indirectly suppress TRPV1 effects on pain and inflammation, by acting at CB1, but directly activate TRPV1 at higher concentrations. Inverse agonists of CB1 also suppressed capsaicin-evoked calcium influx in sensory neuron-derived cells. The authors interpreted these findings as indicating that tonic CB1 activity somehow maintains TRPV1 in a state competent for agonist activation.
Capsaicin-evoked flare responses, heat-evoked pain, and UVB-induced heat hyperalgesia can all be inhibited in human skin by selective TRPV1 antagonists. Interestingly, although anandamide could evoke pain at high concentrations, its vasodilatory effect was achieved at concentrations that were not associated with pain, suggesting a disconnect between influences on afferent versus efferent neuronal activities.
For example, TRPV1-like immunoreactivity has been reported in human mast cells, hair follicle outer root sheath epithelial cells, and keratinocytes. TRPV1 expression has also been reported in human dendritic cells DCs , where its activation suppresses differentiation, 44 providing an additional potential site of action during allergic contact dermatitis.
Finally, cutaneous TRPV1 expression levels change in some human dermatological conditions. Another TRP channel target of cannabinoids is transient receptor potential ankyrin 1 TRPA1 , so-named because of the existence of 16 ankyrin repeats in its amino terminal domain.
Most of the identified TRPA1 agonists are irritant electrophiles such as allyl isothiocyanate mustard oil , cinnamaldehyde, and formaldehyde. Electrophiles activate TRPA1 by covalently alkylating intracellular cysteine residues located among the ankyrin repeats. TRPA1 can alternatively be activated by noncovalent chemical agonists. TRPA1 participates in both acute pain sensation and hyperalgesia. Pain related responses triggered by covalent TRPA1 agonists are reduced by pharmacological antagonism of TRPA1 or by genetic deletion of this channel in mice.
This results in part from sensory neuron-expressed TRPA1 acting downstream of signaling by G protein-coupled receptors for itch-producing peptides or monoamines. TRPA1 agonists produce robust neurogenic inflammation in skin, which can be ablated by either pharmacological antagonism or genetic elimination of TRPA1.
Oxa increased skin expression of 4-hydroxynonenol, providing a potential means of TRPA1 activation in this model. Furthermore, TRPA1 knockout mice exhibited reduced epidermal thickening and reduced skin expression of inflammatory cytokines in this model. For example, in the acetone—ether—water model of chronic dry skin, genetic elimination of TRPA1 not only diminished itch-related behavioral responses, but also suppressed epidermal thickening and the cutaneous upregulation of numerous genes, including keratin 6, aquaporin 3, and IL Neurogenic mechanisms undoubtedly account for some of the proinflammatory cutaneous effects of TRPA1 described above.
This raises the possibility that alterations in inflammatory responses in TRPA1 knockout mice might additionally reflect changes in the innate immune responses of these cells. Although TRPA1 and TRPV1 are capable of functioning as independent channels, they are coexpressed in a subset of peripheral sensory neurons, and growing evidence suggests that these channels can functionally interact.
The mechanisms underlying this reciprocal cross-desensitization are complex, and likely not identical. TRPA1 and TRPV1 can bind to one another, though whether this binding involves the formation of heterotetramers versus binding between two different homotetrameric channels remains unclear. Regardless, the functional interaction of TRPV1 and TRPA1 offers a potential mechanism by which cannabinoids might regulate not only pain and itch perception, but also cutaneous inflammation. AlthoughTRPV2 is robustly expressed in peripheral sensory neurons, 62 extensive examination of pain responses in TRPV2 knockout mice failed to reveal an obvious role for this channel in thermal or mechanical nociception.
TRPV2 might participate in neurogenic inflammation. Thus, while there is abundant circumstantial evidence of TRPV2 involvement in skin biology, more studies will be necessary to clearly define any such roles. TRPV3 knockout mice were initially observed to exhibit a prolonged latency to heat-evoked behavioral withdrawal and to exhibit delayed selection of preferred temperatures on a thermal gradient.
Pain and itch arising from genetic mutation of TRPV3 in humans is discussed below. Studies of both global and keratinocyte-specific TRPV3 knockout mice have revealed that this channel is critical for normal epidermal differentiation and hair morphology. Late embryonic TRPV3 knockout mice exhibited premature epidermal differentiation, compromised epidermal barrier function, abnormal corneocytes, and reduced epidermal transglutaminase activity.
Many of these changes appeared to resolve over time. In addition, throughout life, TRPV3 knockout mice exhibited curly whiskers and abnormalities in body fur.
TRPV3 activation has also been reported to inhibit growth of human hair. Point mutations in TRPV3 can have profound effects on skin. Genetic background also influenced the ability of the Gly Ser mutation to augment the predilection of mice toward chemically evoked allergic contact dermatitis. Strikingly, the ability of mutations at TRPV3 Gly to cause dermatological disease is not confined to rodents. Using whole exome sequencing, Lin et al.
These histological changes are typically accompanied by intense itching. Hair loss and deformities of the digits, including autoamputation, are also observed in some individuals. The Olmsted-associated human TRPV3 mutant variants, like the homologous rodent mutants, exhibited robust spontaneous activity when transfected into cell lines.
These mutants also triggered apoptosis in transfected cells, and, accordingly, histological examination revealed an increase in apoptosis in skin from Olmsted syndrome patients. Some of the affected patients experienced not only plantar keratoderma, but also erythromelalgia, an intermittent reddening of the skin accompanied by intense pain, itch, warmth, and vasodilation. Whether endogenous cannabinoids contribute to the pathophysiology of these conditions, or whether exogenous cannabinoids might be useful to treat patients with TRPV3 mutations, remains to be determined.
It is also not yet clear whether abnormalities in TRPV3 sequence, expression, or regulation might lead to other dermatological diseases. There is also evidence for TRPV4 expression in both sensory and motor neurons. TRPV4 was originally identified as a channel that could be gated by changes in osmolarity.
Recently, two phytocannabinoids, cannabidivarin and tetrahydrocannabivarin, were shown to stimulate TRPV4, while cannabigerovarin, cannabigerolic acid, cannabinol, and cannabigerol were shown to desensitize this channel 81 Table 1. Multiple lines of evidence support a role for TRPV4 in pain sensation. TRPV4 knockout mice were found to exhibit reduced acute mechanically evoked pain behaviors.
One possible contributor to this phenotype was the absence of TRPV4-dependent synthesis and release of endothelin 1 from UVB treated keratinocytes. TRPV4 appears to be important for the temperature-dependent formation of normal epithelial tight junctions between skin keratinocytes in both mice and humans. This function involves TRPV4-dependent calcium entry, with subsequent activation of Rho kinases and actin rearrangement.
Mice lacking TRPV4 were reported to exhibit impaired epidermal barrier function. They also exhibited a thickened stratum corneum, perhaps as a reaction to the former deficit. For example, the keratinocyte-selective knockout of the TRPV4 gene not only reduces pain arising from UVB irradiation, but also suppresses irradiation induced skin damage and inflammatory cell recruitment.
In mice, this channel is essential for cutaneous discrimination of mildly cold temperatures, and also appears to play both positive and negative roles in cold-evoked pain sensation. Immunoreactivity for TRPM8 has been demonstrated in human skin, and is reduced in patients with congenital insensitivity to pain. In summary, cannabinoids can engage numerous targets within the skin, including not only metabotropic receptors, but also multiple members of the TRP family of ion channels.
Cutaneous ionotropic cannabinoid receptors participate in functions related to pain and itch perception, epidermal homeostasis, and the promotion and suppression of dermatitis in both animal models and humans. This situation creates potential opportunities to intervene therapeutically in sensory and inflammatory skin diseases using the chemically rich pharmacology of cannabinoids.
In addition, the experimental accessibility of the skin makes this organ an excellent one in which to uncover principles of intercellular cannabinoid signaling that may be generalizable to the CNS and other less accessible tissues. The value of such an experimentally tractable system is amplified by the multiple examples, described above, in which the effects of a given cannabinoid or a given change in TRP channel activity can produce distinct outcomes, depending on the biological and pharmacological circumstances.
The authors declare the following competing financial interest s: National Center for Biotechnology Information , U. Published online Jun Author information Article notes Copyright and License information Disclaimer. Received Apr 28; Revised Jun 4. This is an open access article published under an ACS AuthorChoice License , which permits copying and redistribution of the article or any adaptations for non-commercial purposes.
This article has been cited by other articles in PMC. Open in a separate window. Transient receptor potential, ion channel, cannabinoids, nociception, pruritis, dermatitis.
Cannabinoid Effects in Skin The skin possesses a robust capacity to synthesize and respond to cannabinoids. The TRP Ion Channel Family The TRP family of ion channels owes its name to the fact that its first identified member, the Drosophila protein Transient Receptor Potential, is a calcium-permeable ion channel whose genetic absence results in a transient electrophysiological response of the Drosophila photoreceptor cells to light.
TRP Channels, Cannabinoids, and Skin As described above, many actions of cannabinoids in skin and elsewhere cannot be explained solely on the basis of actions at metabotropic CB receptors.
TRPV1 Transient receptor potential vanilloid 1 TRPV1 is a nonselective cation channel that was originally discovered as the pharmacological site of action of pungent vanilloid compounds such as capsaicin.
TRP Channel Cannabinoid Receptors in Skin Sensation, Homeostasis, and Inflammation
Jan 17, The endocannabinoid system consists of cellular receptors found in very large . what type of cell it is—nerve cells, immune cells, skin cells, muscle cells, secretory cells Below are a few interesting facts about the ECS in general: . to eat them, and, subsequently, spreading the spores to nearby surfaces. Skin Care Classes Meditation GIFT CERTIFICATES & PACKAGES Plan Your Visit The body's endocannabinoid system (ECS) is a vital molecular system for Cannabinoid receptors sit on the surface of cells and “listen” to conditions outside the cell. Below we will consider examples of how the ECS helps maintain. Oct 4, Let's explore the magic that hides beneath the popular surface of cannabis. the endocannabinoid system is the ultimate balance system of our . as an appetite stimulant, an antibacterial for skin infections, a cancer cell.